早期持续性淋巴细胞减少与合并及不合并脓毒症的危重患者死亡风险
该回顾性数据库分析纳入2015年1月至2018年12月非择期入住ICU的8,507例患者,其中7,605例(89.4%)在前4天有两次绝对淋巴细胞计数(ALC)记录,1,482例(19.5%)为脓毒症。以ALC<1.0×10⁹/L和<0.75×10⁹/L两个阈值定义早期持续性淋巴细胞减少。持续淋巴细胞减少(ALC<1.0)在脓毒症患者中占49.1%,在非脓毒症患者中占37.6%;其院内死亡独立风险比在脓毒症患者中为1.89(95%CI 1.32-2.71,P=0.0005),在非脓毒症患者中为1.17(95%CI 1.02-1.35,P=0.0246)。作者认为淋巴细胞减少是候选的可治疗特征,逆转淋巴细胞减少的药物应在危重患者中开展试验。
要点
- 脓毒症患者早期持续性淋巴细胞减少(ALC<1.0×10⁹/L)发生率49.1%(728/1,482),非脓毒症患者37.6%(2,302/6,123)。
- ALC<1.0×10⁹/L持续者院内死亡率18.5%(562/3,030),无持续淋巴细胞减少者9.6%(439/4,575)。
- 脓毒症患者持续淋巴细胞减少(ALC<1.0)与院内死亡独立相关:HR 1.89(95%CI 1.32-2.71,P=0.0005)。
- 非脓毒症患者该关联较弱但仍独立:HR 1.17(95%CI 1.02-1.35,P=0.0246)。
- ALC<0.75×10⁹/L阈值下持续淋巴细胞减少在脓毒症患者中占32.9%(487/1,482),非脓毒症患者中占18.4%(1,125/6,123)。
适用人群与场景
- 2015年1月至2018年12月非择期入住ICU的患者。
- 脓毒症定义:急性生理与慢性健康评估III入ICU诊断代码包含脓毒症,或编码为感染且序贯器官衰竭评估评分≥2。
- 纳入分析需在ICU前4天内记录两次绝对淋巴细胞计数(ALC);8,507例 eligible 患者中7,605例(89.4%)符合。
诊断标准与关键阈值
- 早期持续性淋巴细胞减少定义:基于ICU前4天内两次符合条件的ALC值,阈值分别为ALC<1.0×10⁹/L和ALC<0.75×10⁹/L。
- 脓毒症判定:APACHE III入ICU诊断代码包含脓毒症,或感染编码联合SOFA评分≥2。
研究设计与关键结果
- 研究类型:回顾性数据库分析;样本量8,507例 eligible,7,605例(89.4%)有两次ALC记录,其中脓毒症1,482例(19.5%)。
- 持续淋巴细胞减少(ALC<1.0×10⁹/L)在脓毒症患者中728/1,482(49.1%),非脓毒症患者中2,302/6,123(37.6%)。
- 持续淋巴细胞减少(ALC<0.75×10⁹/L)在脓毒症患者中487/1,482(32.9%),非脓毒症患者中1,125/6,123(18.4%)。
- ALC<1.0×10⁹/L持续者3,030例中562例(18.5%)院内死亡,无持续淋巴细胞减少者4,575例中439例(9.6%)死亡。
- 持续淋巴细胞减少为全因院内死亡的独立危险因素;脓毒症患者ALC<1.0×10⁹/L的死亡HR 1.89(95%CI 1.32-2.71,P=0.0005),非脓毒症患者HR 1.17(95%CI 1.02-1.35,P=0.0246)。
证据类型、等级与局限
- 证据类型:回顾性数据库分析。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,早期持续性淋巴细胞减少在危重患者中常见,且与合并及不合并脓毒症患者的死亡风险增加相关;尽管在脓毒症患者中关联更强,淋巴细胞减少是候选的可治疗特征。
- 作者建议,逆转淋巴细胞减少的药物应在危重患者中开展试验。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
Purpose: To examine the relationship of early persistent lymphopenia with hospital survival in critically ill patients with and without sepsis to assess whether it can be considered a treatable trait. Methods: Retrospective database analysis of patients with nonelective admission to intensive care units (ICUs) during January 2015 to December 2018. Patients were classified as having sepsis if the Acute Physiology and Chronic Health Evaluation III admission diagnostic code included sepsis or coded for an infection combined with a Sequential Organ Failure Assessment score of ≥2. We defined early persistent lymphopenia at two thresholds (absolute lymphocyte count [ALC] <1.0 and <0.75 × 10 9 /L) based on two qualifying values recorded during the first 4 days in ICU. The main outcome measure was time to in-hospital death. Results: Of 8,507 eligible patients, 7,605 (89.4%) had two ALCs recorded during their first 4 days in ICU; of these, 1,482 (19.5%) had sepsis. Persistent lymphopenia (ALC <1.0) was present in 728 of 1,482 (49.1%) and 2,302 of 6,123 (37.6%) patients with and without sepsis, respectively. For ALC <0.75, the results were 487 of 1,482 (32.9%) and 1,125 of 6,123 (18.4%), respectively. Of 3,030 patients with persistent lymphopenia (ALC <1.0), 562 (18.5%) died compared with 439 of 4,575 (9.6%) without persistent lymphopenia. Persistent lymphopenia was an independent risk factor for in-hospital death in all patients. The hazard ratios for death at ALC <1.0 were 1.89 (95% confidence interval, 1.32-2.71; P = 0.0005) and 1.17 (95% confidence interval, 1.02-1.35; P = 0.0246) in patients with and without sepsis respectively. Conclusions: Early persistent lymphopenia is common in critically ill patients and associated with increased risk of death in patients with and without sepsis. Although the association is stronger in patients with sepsis, lymphopenia is a candidate to be considered a treatable trait; drugs that reverse lymphopenia should be trialed in critically ill patients.
参考来源
- Adigbli D, Liu R, Meyer J, et al. EARLY PERSISTENT LYMPHOPENIA AND RISK OF DEATH IN CRITICALLY ILL PATIENTS WITH AND WITHOUT SEPSIS. Shock. 2023. PMID: 38151771. doi:10.1097/SHK.0000000000002284
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。